Compare RLJ & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | CSTL |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2011 | 2019 |
| Metric | RLJ | CSTL |
|---|---|---|
| Price | $7.65 | $40.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $8.75 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 1.7M | 331.6K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 7.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $1,351,163,000.00 | $343,530,000.00 |
| Revenue This Year | N/A | $2.54 |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | $173.91 | ★ N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $6.16 | $14.59 |
| 52 Week High | $10.25 | $42.18 |
| Indicator | RLJ | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 57.91 |
| Support Level | $7.48 | $38.73 |
| Resistance Level | $7.82 | $41.60 |
| Average True Range (ATR) | 0.20 | 1.58 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 61.11 | 62.75 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.